Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Preventing Rheumatoid Arthritis Requires a Mixed Population of Regulatory T-cells

By LabMedica International staff writers
Posted on 23 May 2012
A recent article discussed the latest thinking regarding the molecular aspects of how the immune system guards itself from the development of autoimmune disorders such as rheumatoid arthritis and why this system sometimes fails.

A white blood cell cocktail containing CD4+CD25+Foxp3+ regulatory T-cells (Tregs) is required to restrain the immune system from mounting an autoaggressive systemic inflammatory response. More...
Rheumatoid arthritis is an autoimmune disorder that occurs when this protection fails and the immune system attacks the synovium, the membrane that lines all the joints of the body. It is a common disorder that causes pain, redness, and swelling around the joints. It has been estimated that approximately one percent of the adult population, worldwide, suffers from rheumatoid arthritis.

Investigators at The Wistar Institute (Philadelphia, PA; USA) used a mouse model of spontaneous autoimmune arthritis. These animals had been genetically engineered to express a “self” molecule - a clonotypic T-cell receptor (TCR) - that induced arthritis by an IL-17–dependent mechanism. The investigators then determined how TCR specificity contributed to Treg activity.

Results published in the May 1, 2012, issue of the Journal of Immunology revealed that administration of polyclonal Tregs suppressed Th17 cell formation and prevented arthritis development. Treatment with Tregs that expressed only the clonotypic TCR did not prevent development of arthritis.

“Our results show, surprisingly, that suppressing the immune response against a single target will not shut down the inflammatory response that causes rheumatoid arthritis,” said senior author Dr. Andrew J. Caton, professor in The Wistar Institute’s tumor microenvironment and metastasis program. “Instead, an array of inflammation-stimulating antigens may be involved in causing the disease, since our study shows that an array of regulatory T-cells is required to temper the immune system’s attack on joints.”

“The big unanswered question of rheumatoid arthritis is ‘why are joints targeted’?” said Dr. Caton. “Of all the tissues in the body, of all the places our immune system could attack, this question remains. One idea is that the immune system is not deliberately attacking joints in patients with rheumatoid arthritis, but the joint inflammation is a side effect of the natural tendency of these cells to accumulate in these areas of the body.”

Related Links:

The Wistar Institute



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.